Australia TGA ARTG recordMedicine administration kit, percutaneous, medicated, single-use
Australia TGA ARTG Registered Device · Sanofi-Aventis Australia Pty Ltd · Sanofi Pasteur Inc · Class IIa · Started March 07, 2019
Good Name: Sanofi-Aventis Australia Pty Ltd - Medicine administration kit, percutaneous, medicated, single-use
- Risk Class
- Class IIa
- Product Type
- Procedure Pack
- ARTG Category
- General
- Start Date
- March 07, 2019
- Effective Date
- March 07, 2019
- Country
- United States of America
- Address
- 1 Discovery Drive, SWIFTWATER, PA, 18370
Fluquadri (AUST R 213963) is indicated for active immunisation of influenza disease and is available in 0.5mL injection pre-filled needle-free syringe. Seperate needle (either 5 or 10) will be provided in each pack of Fluquadri syringe for administraiton.
Access comprehensive regulatory information for Medicine administration kit, percutaneous, medicated, single-use in the Australia medical device market through Pure Global AI's free TGA ARTG database. This Class IIa is sponsored by Sanofi-Aventis Australia Pty Ltd, manufactured by Sanofi Pasteur Inc in United States of America. The device registration started on March 07, 2019.
This page provides complete registration details including sponsor information, manufacturer details, and regulatory compliance data from the official Australia TGA ARTG medical device database. Pure Global AI offers free access to Australia's complete medical device registry with 131,000+ devices, helping global MedTech companies navigate TGA regulations efficiently.